Cargando…

Respiratory Syncytial Virus Prevention: A New Era of Vaccines

Respiratory syncytial virus (RSV) is a pathogen that primarily affects the respiratory system, leading to upper and lower respiratory tract infections. Children, individuals aged 60 and above, and individuals with impaired immune systems are more susceptible to developing RSV lower respiratory tract...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Calvin Yee Fen, Khan, Salman J, Vishal, Fnu, Alam, Sadaf, Murtaza, Syeda Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565597/
https://www.ncbi.nlm.nih.gov/pubmed/37829940
http://dx.doi.org/10.7759/cureus.45012
_version_ 1785118728618246144
author Lee, Calvin Yee Fen
Khan, Salman J
Vishal, Fnu
Alam, Sadaf
Murtaza, Syeda Fatima
author_facet Lee, Calvin Yee Fen
Khan, Salman J
Vishal, Fnu
Alam, Sadaf
Murtaza, Syeda Fatima
author_sort Lee, Calvin Yee Fen
collection PubMed
description Respiratory syncytial virus (RSV) is a pathogen that primarily affects the respiratory system, leading to upper and lower respiratory tract infections. Children, individuals aged 60 and above, and individuals with impaired immune systems are more susceptible to developing RSV lower respiratory tract infections (LRTIs), which can result in fatalities in some instances. Symptoms of LRTI include shortness of breath, wheezing, pneumonia, and bronchiolitis. Current management of RSV-LRTI includes conservative and symptomatic treatment. The Food and Drug Administration (FDA) recently approved two vaccines that effectively prevent acute and severe RSV-LRTI requiring hospitalizations. Nirsevimab (Beyfortus) is approved for infants born at 35 weeks of gestation and above. At the same time, RSVPreF3 OA (Arexvy) is recommended for adults aged 60 and older. Both vaccines are effective against the two major strains of RSV and require single doses to induce immunity. In this article, we will discuss the mechanism of action, effectiveness, and side effects of these novel vaccines and their possible impact.
format Online
Article
Text
id pubmed-10565597
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105655972023-10-12 Respiratory Syncytial Virus Prevention: A New Era of Vaccines Lee, Calvin Yee Fen Khan, Salman J Vishal, Fnu Alam, Sadaf Murtaza, Syeda Fatima Cureus Preventive Medicine Respiratory syncytial virus (RSV) is a pathogen that primarily affects the respiratory system, leading to upper and lower respiratory tract infections. Children, individuals aged 60 and above, and individuals with impaired immune systems are more susceptible to developing RSV lower respiratory tract infections (LRTIs), which can result in fatalities in some instances. Symptoms of LRTI include shortness of breath, wheezing, pneumonia, and bronchiolitis. Current management of RSV-LRTI includes conservative and symptomatic treatment. The Food and Drug Administration (FDA) recently approved two vaccines that effectively prevent acute and severe RSV-LRTI requiring hospitalizations. Nirsevimab (Beyfortus) is approved for infants born at 35 weeks of gestation and above. At the same time, RSVPreF3 OA (Arexvy) is recommended for adults aged 60 and older. Both vaccines are effective against the two major strains of RSV and require single doses to induce immunity. In this article, we will discuss the mechanism of action, effectiveness, and side effects of these novel vaccines and their possible impact. Cureus 2023-09-11 /pmc/articles/PMC10565597/ /pubmed/37829940 http://dx.doi.org/10.7759/cureus.45012 Text en Copyright © 2023, Lee et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Preventive Medicine
Lee, Calvin Yee Fen
Khan, Salman J
Vishal, Fnu
Alam, Sadaf
Murtaza, Syeda Fatima
Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title_full Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title_fullStr Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title_full_unstemmed Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title_short Respiratory Syncytial Virus Prevention: A New Era of Vaccines
title_sort respiratory syncytial virus prevention: a new era of vaccines
topic Preventive Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565597/
https://www.ncbi.nlm.nih.gov/pubmed/37829940
http://dx.doi.org/10.7759/cureus.45012
work_keys_str_mv AT leecalvinyeefen respiratorysyncytialviruspreventionaneweraofvaccines
AT khansalmanj respiratorysyncytialviruspreventionaneweraofvaccines
AT vishalfnu respiratorysyncytialviruspreventionaneweraofvaccines
AT alamsadaf respiratorysyncytialviruspreventionaneweraofvaccines
AT murtazasyedafatima respiratorysyncytialviruspreventionaneweraofvaccines